• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Neoleukin Therapeutics, Inc. - Common Stock (NQ:NLTX)

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EST, Dec 18, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Neoleukin Therapeutics, Inc. - Common Stock

    Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
    From Neoleukin Therapeutics, Inc.
    Via GlobeNewswire
    Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
    From Neoleukin Therapeutics, Inc.
    Via GlobeNewswire
    NEOLEUKIN THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX
    From Kahn Swick & Foti, LLC
    Via Business Wire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sculptor Capital Management Inc. (NYSE – SCU), Neoleukin Therapeutics, Inc. (Nasdaq - NLTX), Pardes Bioscience, Inc. (Nasdaq – PRDS), Great Ajax Corp. (NYSE – AJX)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Neoleukin Therapeutics, Inc. (Nasdaq - NLTX), Pardes Bioscience, Inc. (Nasdaq – PRDS), Kaleyra, Inc. (NYSE – KLR), Great Ajax Corp. (NYSE – AJX)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    NLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Neurogene and Neoleukin Announce Definitive Merger Agreement
    From Neoleukin Therapeutics, Inc.
    Via GlobeNewswire
    Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition
    From Neoleukin Therapeutics, Inc.
    Via GlobeNewswire
    Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting
    Targeted, precision-tuned agonist of IL-2 receptor selectively expands regulatory T cells 
    From Neoleukin Therapeutics, Inc.
    Via GlobeNewswire
    Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update
    From Neoleukin Therapeutics, Inc.
    Via GlobeNewswire
    Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting
    From Neoleukin Therapeutics, Inc.
    Via GlobeNewswire
    Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
    From Neoleukin Therapeutics, Inc.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.